Peter Cheverton

704 total citations
18 papers, 529 citations indexed

About

Peter Cheverton is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Peter Cheverton has authored 18 papers receiving a total of 529 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 9 papers in Molecular Biology and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Peter Cheverton's work include Cancer Treatment and Pharmacology (10 papers), Cancer therapeutics and mechanisms (7 papers) and Colorectal Cancer Treatments and Studies (4 papers). Peter Cheverton is often cited by papers focused on Cancer Treatment and Pharmacology (10 papers), Cancer therapeutics and mechanisms (7 papers) and Colorectal Cancer Treatments and Studies (4 papers). Peter Cheverton collaborates with scholars based in United Kingdom, United States and Japan. Peter Cheverton's co-authors include D M Dent, I. D. Werner, P. Brice, Ben Novis, Amy Peterson, William E. Carson, Kevin B. Kim, Daniel S. Chen, Jeffrey A. Sosman and Hoa Nguyen and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Clinical Cancer Research.

In The Last Decade

Peter Cheverton

18 papers receiving 504 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Peter Cheverton United Kingdom 11 313 245 137 58 52 18 529
Nicoletta Staropoli Italy 14 350 1.1× 233 1.0× 112 0.8× 40 0.7× 80 1.5× 42 617
Zhiguo Luo China 16 276 0.9× 240 1.0× 172 1.3× 53 0.9× 32 0.6× 60 571
E. Dalmau Spain 10 251 0.8× 346 1.4× 273 2.0× 73 1.3× 16 0.3× 27 695
Preeti Trisal United States 6 413 1.3× 181 0.7× 98 0.7× 33 0.6× 63 1.2× 11 554
Miwa Nishida Japan 6 322 1.0× 156 0.6× 93 0.7× 69 1.2× 20 0.4× 7 469
Alessandro Perez Italy 15 272 0.9× 301 1.2× 206 1.5× 23 0.4× 40 0.8× 41 693
Andrea Ravelli Italy 10 288 0.9× 200 0.8× 251 1.8× 36 0.6× 53 1.0× 15 543
H.J. Lenz United States 9 366 1.2× 250 1.0× 78 0.6× 56 1.0× 49 0.9× 24 551
Hongle Li China 16 220 0.7× 421 1.7× 191 1.4× 76 1.3× 74 1.4× 44 724
Xuelian Chen China 12 462 1.5× 218 0.9× 209 1.5× 149 2.6× 81 1.6× 36 779

Countries citing papers authored by Peter Cheverton

Since Specialization
Citations

This map shows the geographic impact of Peter Cheverton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Cheverton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Cheverton more than expected).

Fields of papers citing papers by Peter Cheverton

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Cheverton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Cheverton. The network helps show where Peter Cheverton may publish in the future.

Co-authorship network of co-authors of Peter Cheverton

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Cheverton. A scholar is included among the top collaborators of Peter Cheverton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Cheverton. Peter Cheverton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Cheverton, Peter, et al.. (2022). Development and validation of a predictive model to guide the use of plerixafor in pediatric population. Bone Marrow Transplantation. 57(12). 1827–1832. 2 indexed citations
2.
Andritsos, Leslie A., John C. Byrd, Peter Cheverton, et al.. (2019). A multicenter phase 1 study of plerixafor and rituximab in patients with chronic lymphocytic leukemia. Leukemia & lymphoma. 60(14). 3461–3469. 22 indexed citations
3.
4.
Micallef, Ivana N., Patrick J. Stiff, Auayporn Nademanee, et al.. (2018). Plerixafor Plus Granulocyte Colony-Stimulating Factor for Patients with Non-Hodgkin Lymphoma and Multiple Myeloma: Long-Term Follow-Up Report. Biology of Blood and Marrow Transplantation. 24(6). 1187–1195. 36 indexed citations
5.
Kim, Kevin B., Jeffrey A. Sosman, John P. Fruehauf, et al.. (2011). BEAM: A Randomized Phase II Study Evaluating the Activity of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Melanoma. Journal of Clinical Oncology. 30(1). 34–41. 148 indexed citations
6.
Hegde, Priti S., Baolin Xing, Steven O’Day, et al.. (2010). Biomarkers of treatment benefit in a randomized phase II study of bevacizumab in combination with carboplatin and paclitaxel in metastatic melanoma patients (BEAM).. Journal of Clinical Oncology. 28(15_suppl). 10563–10563. 1 indexed citations
7.
Soepenberg, Otto, Maja J.A. de Jonge, Alex Sparreboom, et al.. (2005). Phase I and Pharmacokinetic Study of DE-310 in Patients with Advanced Solid Tumors. Clinical Cancer Research. 11(2). 703–711. 56 indexed citations
8.
Wente, Moritz N., Jörg Kleeff, Markus W. Büchler, et al.. (2005). DE-310, a macromolecular prodrug of the topoisomerase-I-inhibitor exatecan (DX-8951), in patients with operable solid tumors. Investigational New Drugs. 23(4). 339–347. 15 indexed citations
9.
Ardalan, Bach, et al.. (2005). Phase II trial of DJ-927 as a second-line treatment for colorectal cancer demonstrates objective responses. Journal of Clinical Oncology. 23(16_suppl). 3654–3654. 4 indexed citations
10.
11.
Cheverton, Peter, Helmut Frieß, Csilla András, et al.. (2004). Phase III results of exatecan (DX-8951f) versus gemcitabine (Gem) in chemotherapy-naïve patients with advanced pancreatic cancer (APC). Journal of Clinical Oncology. 22(14_suppl). 4005–4005. 41 indexed citations
12.
13.
14.
Braybrooke, Jeremy, C. Manegold, K. Mattson, et al.. (2003). Phase II study of exatecan mesylate (DX-8951f) as first line therapy for advanced non-small cell lung cancer. Lung Cancer. 41(2). 215–219. 15 indexed citations
15.
Jager, Robert De, Peter Cheverton, John Coyle, et al.. (2000). DX‐8951f: Summary of Phase I Clinical Trials. Annals of the New York Academy of Sciences. 922(1). 260–273. 32 indexed citations
16.
Talbot, D C, Shane White, K. Mattson, et al.. (2000). Phase II study of Exatecan Mesylate (DX-8951f) in advanced NSCLC. Lung Cancer. 29(1). 55–55. 3 indexed citations
17.
18.
Dent, D M, I. D. Werner, Ben Novis, Peter Cheverton, & P. Brice. (1979). Prospective randomized trial of combined oncological therapy for gastric carcinoma. Cancer. 44(2). 385–391. 81 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nicoletta Staropoli Breakdown of academic impact, for papers by Zhiguo Luo Breakdown of academic impact, for papers by E. Dalmau Breakdown of academic impact, for papers by Preeti Trisal Breakdown of academic impact, for papers by Miwa Nishida Breakdown of academic impact, for papers by Alessandro Perez Breakdown of academic impact, for papers by Andrea Ravelli Breakdown of academic impact, for papers by H.J. Lenz Breakdown of academic impact, for papers by Hongle Li Breakdown of academic impact, for papers by Xuelian Chen
Rankless by CCL
2026